Brain Cancer Clinical Trials in Arizona

Showing 41-60 of 152 trials

Infigratinib in Recurrent High-Grade Glioma Patients

NCT04424966

This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation which are scheduled for resection. In the lead-in cohort, a total of 20 participants will be enrolled into the proposed phase 0 clinical trial. Participants will be administered infigratinib prior to surgical resection of their tumor.

GliomaGlioblastomaGBM

Nader Sanai7 participantsStarted Jul 2020

Chandler, Arizona, United States • Phoenix, Arizona, United States • Scottsdale, Arizona, United States

COMPLETEDPhase 331 miles

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

NCT03345095

The standard of care for newly diagnosed glioblastoma includes surgery, involved-field radiotherapy, and concomitant and six cycles of maintenance temozolomide chemotherapy, however the prognosis remains dismal. Marizomib has been tested in patients with newly diagnosed and recurrent glioblastoma in phase I and phase II studies. In patients with recurrent glioblastoma, marizomib was administered as a single agent or in combination with bevacizumab (NCT02330562). Based on encouraging observations, a phase I/II trial of marizomib in combination with Temozolomide+Radiotherapy(TMZ/RT) followed by Temozolomide (TMZ) in newly diagnosed glioblastoma has been launched (NCT02903069) which explores safety and tolerability of this triple combination and which shall help to determine the dose for further clinical trials in glioblastoma. In this context, given that marizomib has been established as a safe addition to the standard TMZ/RT --\>TMZ, a phase III study is considered essential to establishing its impact on overall survival.

Newly Diagnosed Glioblastoma

European Organisation for Research and Treatment of Cancer - EORTC749 participantsStarted Jul 2018

Scottsdale, Arizona, United States • Orange, California, United States • San Francisco, California, United States +79 more locations

Infigratinib in Recurrent High-Grade Glioma Patients

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

Brain Cancer Trials in Other Cities

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Clinical Trial of BMS-986504 in Recurrent GBM Patients

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

VB-111 in Surgically Accessible Recurrent/Progressive GBM

A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Other Conditions in Arizona